Related Experiment Video
Updated: Aug 14, 2026

Nanosensors to Detect Protease Activity In Vivo for Noninvasive Diagnostics
Published on: July 16, 2018
NAAG peptidase inhibitors and their potential for diagnosis and therapy
Jia Zhou1, Joseph H Neale, Martin G Pomper
1Acenta Discovery, Inc., 9030 South Rita Road, Suite 300, Tucson, Arizona 85747, USA. jia.zhou@acentadiscovery.com
Abstract:
Modulation of N-acetyl-L-aspartyl-L-glutamate peptidase activity with small-molecule inhibitors holds promise for a wide variety of diseases that involve glutamatergic transmission, and has implications for the diagnosis and therapy of cancer. This new class of compounds, of which at least one has entered clinical trials and proven to be well tolerated, has demonstrated efficacy in experimental models of pain, schizophrenia, amyotrophic lateral sclerosis, traumatic brain injury and, when appropriately functionalized, can image prostate cancer. Further investigation of these promising drug candidates will be needed to bring them to the marketplace. The recent publication of the X-ray crystal structure for the enzymatic target of these compounds should facilitate the development of other new agents with enhanced activity that could improve both the diagnosis and treatment of neurological disorders.
Related Concept Videos
Inhibitors of Gram-positive Cell Wall Synthesis
Acute Pyelonephritis II: Diagnostic Studies and Management
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Inhibitors of Bacterial Protein Synthesis
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:

